급성 간헐성 포르피린증 시장 규모, 점유율, 성장 분석 : 진단별, 치료법별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Acute Intermittent Porphyria Market size was valued at USD 4.45 Billion in 2024 and is poised to grow from USD 4.59 Billion in 2025 to USD 5.86 Billion by 2033, growing at a CAGR of 3.1% during the forecast period (2026-2033).

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth, driven by increased awareness, advancements in diagnostic techniques, and innovative treatment developments. As a rare genetic disorder affecting heme production, AIP is garnering attention in the healthcare sector, thanks in part to improved diagnostic tools like genetic testing that enable earlier and more accurate identification of patients. The pharmaceutical industry's commitment to research and development is fostering new therapeutic options, while enhanced patient education is crucial for effective symptom management. Despite these advancements, challenges remain, including underdiagnosis and a limited range of treatment alternatives. A collaborative approach among healthcare providers, researchers, and pharmaceutical companies is essential to navigate the complexities and fully realize the potential of the AIP market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Acute Intermittent Porphyria market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Acute Intermittent Porphyria Market Segments Analysis

Global Acute Intermittent Porphyria Market is segmented by Diagnosis, Treatment, End Users and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, DNA Test and Serum Test. Based on Treatment, the market is segmented into Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions. Based on End Users, the market is segmented into Hospitals, Clinics and Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Acute Intermittent Porphyria Market

The growing emphasis on advanced diagnostic techniques has significantly improved the identification of Acute Intermittent Porphyria (AIP) cases, enabling timely intervention and management. Furthermore, the development of new treatment options, such as hematin infusions and innovative RNA interference (RNAi) therapies like givosiran, provides more effective strategies for managing acute episodes and long-term symptom control. This combination of enhanced detection and novel therapeutic approaches is driving the AIP market forward, ensuring patients receive better care and improved health outcomes. The integration of these advancements continues to transform the landscape for those affected by this condition.

Restraints in the Acute Intermittent Porphyria Market

A significant challenge in the Acute Intermittent Porphyria market is the underdiagnosis of the condition, which is exacerbated by its rarity and the intricate nature of its symptoms. This complexity often results in delays or missed diagnoses for those affected. Furthermore, the treatment landscape is constrained by the limited options available, primarily focusing on alleviating symptoms rather than offering a definitive cure. This combination of diagnostic difficulties and restricted therapeutic alternatives hinders market growth and can prevent patients from receiving timely and effective care. Addressing these issues is essential for improving outcomes and expanding market potential.

Market Trends of the Acute Intermittent Porphyria Market

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth driven by advances in genetic testing technologies, which facilitate more accurate and timely diagnoses for patients. This shift towards precision medicine is bolstered by the emergence of innovative treatments such as RNA interference (RNAi) therapies, including medications like givosiran, that specifically target the genetic basis of AIP. These developments not only enhance therapeutic efficacy but also improve patient outcomes, thereby expanding the patient pool and driving demand in the market. As awareness and understanding of AIP increase, the landscape for diagnosis and treatment is poised for robust evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Acute Intermittent Porphyria Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Test
• Urine Test
• DNA Test
• Serum Test

Global Acute Intermittent Porphyria Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

Global Acute Intermittent Porphyria Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Research Centers

Global Acute Intermittent Porphyria Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, End Users)
  • US
  • Canada
• Europe (Diagnosis, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clinuvel Pharmaceuticals Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luitpold Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations